Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 15;63(12):1615-1618.
doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Ryan K Shields  1   2   3 , Brian A Potoski  1   4   2 , Ghady Haidar  1 , Binghua Hao  3 , Yohei Doi  1 , Liang Chen  5 , Ellen G Press  1 , Barry N Kreiswirth  5 , Cornelius J Clancy  1   3   6 , M Hong Nguyen  1   2   3
Affiliations

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Ryan K Shields et al. Clin Infect Dis. .

Abstract

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

Keywords: Klebsiella pneumoniae carbapenemase; carbapenem-resistant Enterobacteriaceae; ceftazidime-avibactam resistance.

PubMed Disclaimer

Comment in

References

    1. Acycaz (Ceftazidime-avibactam). Prescribing information. Cincinnati, Ohio: Forest Pharmaceuticals, Inc, 2016.
    1. Shields RK, Clancy CJ, Hao B et al. . Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2015; 59:5793–7. - PMC - PubMed
    1. Center for Disease Control and Prevention. Healthcare-associated infections (HAIs): CRE definition. Available at: https://www.cdc.gov/hai/organisms/cre/definition.html. Accessed 6 April 2016.
    1. Centers for Disease Control and Prevention/National Healthcare Safety Network Surveillance Definitions for Specific Types of Infections (January 2016). Available at: http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf Accessed 1 March.
    1. Clancy CJ, Chen L, Shields RK et al. . Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 2013; 13:2619–33. - PMC - PubMed